{"id":956059,"date":"2026-04-29T11:03:22","date_gmt":"2026-04-29T15:03:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/"},"modified":"2026-04-29T11:03:22","modified_gmt":"2026-04-29T15:03:22","slug":"retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/","title":{"rendered":"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Dallas, TX, April  29, 2026  (GLOBE NEWSWIRE) &#8212; PatentVest today released its latest <i>PatentVest Pulse<\/i>:<b> \u201cThe Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.\u201d<\/b><\/p>\n<p>In April 2026, Eli Lilly\u2019s retatrutide delivered <b>28.7% mean weight loss, <\/b>the first non-surgical therapy to match bariatric outcomes.<\/p>\n<p>But the milestone didn\u2019t end the race. It changes it.<\/p>\n<p>Everyone is focused on the 28.7%,\u201d said Will Rosellini &#8211; Chief IP Officer at PatentVest.<br \/>\u201cBut that number is just the entry point. Once the mechanism works, the question shifts from who can build it to who controls it, and that\u2019s where most teams are underprepared.\u201d<\/p>\n<p>Across the landscape:<\/p>\n<ul>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <b>Novo Nordisk<\/b> is building across multiple triple-agonist assets<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <b>Pfizer<\/b> has entered through acquisition<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <b>Hanmi<\/b> is advancing the only clinical-stage small-molecule triple<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <b>Innovent, Hengrui, and multiple Chinese sponsors<\/b> are scaling pipeline depth<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <b>Sanofi<\/b> holds the largest IP position without a disclosed asset<\/li>\n<\/ul>\n<p>27 programs. One validated mechanism.<\/p>\n<p>\n        <b>What shifts now:<\/b>\n      <\/p>\n<p>The question is no longer who can build these drugs.<\/p>\n<p>It\u2019s:<\/p>\n<ul>\n<li style=\"margin-top:0in;margin-bottom:0in\">Who can operate around the IP<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">Who gets blocked<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">And who ends up paying to participate<\/li>\n<\/ul>\n<p>Because 28.7% doesn\u2019t hold in the real world. And the gap between trial results and actual outcomes becomes the real battleground.<\/p>\n<p>We call it:<\/p>\n<p>\n        <b>The Last 20%.<\/b>\n      <\/p>\n<p>This report maps:<\/p>\n<ul>\n<li style=\"margin-top:0in;margin-bottom:0in\">The full pipeline<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">The deal layer shaping access<\/li>\n<li style=\"margin-top:0in;margin-bottom:0in\">And the IP structure that will define who captures value<\/li>\n<\/ul>\n<p>\n        <b>About PatentVest <\/b>\n      <\/p>\n<p>PatentVest is where intellectual property strategy meets execution. We partner with innovators and in-house legal teams to turn patent portfolios into value creation, combining seasoned IP counsel, analyst-driven intelligence, and a technology stack purpose-built for modern IP work. All at Better Quality and Greater Efficiency than Big Law. Whether you&#8217;re protecting a breakthrough, evaluating a target, or building toward a liquidity event, our integrated Strategy and Legal Services help you move with clarity and speed. <b>Let&#8217;s talk about what your IP could be doing for you.<\/b><\/p>\n<p>Reach out to explore how PatentVest can support your next move.<\/p>\n<p>\n        <strong>Media Contact:<\/p>\n<p><\/strong>For more information or inquiries, please contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ac7uCdi4_QQfTdrt5lYqkt1Q7qR0ZWGigrLN87xMDTfD2L3CMA2Z32y-bTsVWRQstm7QqooR6toyo5lzJ29JgxzgnbKpFp9rXmp4tWTB--U=\" rel=\"nofollow\" target=\"_blank\">info@patentvest.com<\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWYzOGZhNGMtNjFkMi00NTNkLWI4YWYtODhmMmU4ZjJjNmI2LTUwMDEyNDY2Ni0yMDI2LTA0LTI5LWVu\/tiny\/PatentVest-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) &#8212; PatentVest today released its latest PatentVest Pulse: \u201cThe Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.\u201d In April 2026, Eli Lilly\u2019s retatrutide delivered 28.7% mean weight loss, the first non-surgical therapy to match bariatric outcomes. But the milestone didn\u2019t end the race. It changes it. Everyone is focused on the 28.7%,\u201d said Will Rosellini &#8211; Chief IP Officer at PatentVest.\u201cBut that number is just the entry point. Once the mechanism works, the question shifts from who can build it to who controls it, and that\u2019s where most teams are underprepared.\u201d Across the landscape: Novo Nordisk is building across multiple triple-agonist assets Pfizer has entered &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-956059","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) &#8212; PatentVest today released its latest PatentVest Pulse: \u201cThe Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.\u201d In April 2026, Eli Lilly\u2019s retatrutide delivered 28.7% mean weight loss, the first non-surgical therapy to match bariatric outcomes. But the milestone didn\u2019t end the race. It changes it. Everyone is focused on the 28.7%,\u201d said Will Rosellini &#8211; Chief IP Officer at PatentVest.\u201cBut that number is just the entry point. Once the mechanism works, the question shifts from who can build it to who controls it, and that\u2019s where most teams are underprepared.\u201d Across the landscape: Novo Nordisk is building across multiple triple-agonist assets Pfizer has entered &hellip; Continue reading &quot;Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-29T15:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started\",\"datePublished\":\"2026-04-29T15:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/\"},\"wordCount\":353,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/\",\"name\":\"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==\",\"datePublished\":\"2026-04-29T15:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/","og_locale":"en_US","og_type":"article","og_title":"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - Market Newsdesk","og_description":"Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) &#8212; PatentVest today released its latest PatentVest Pulse: \u201cThe Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.\u201d In April 2026, Eli Lilly\u2019s retatrutide delivered 28.7% mean weight loss, the first non-surgical therapy to match bariatric outcomes. But the milestone didn\u2019t end the race. It changes it. Everyone is focused on the 28.7%,\u201d said Will Rosellini &#8211; Chief IP Officer at PatentVest.\u201cBut that number is just the entry point. Once the mechanism works, the question shifts from who can build it to who controls it, and that\u2019s where most teams are underprepared.\u201d Across the landscape: Novo Nordisk is building across multiple triple-agonist assets Pfizer has entered &hellip; Continue reading \"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-29T15:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started","datePublished":"2026-04-29T15:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/"},"wordCount":353,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/","name":"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==","datePublished":"2026-04-29T15:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwOTU1OSM3NTczMDk5IzUwMDEyNDY2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=956059"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956059\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=956059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=956059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=956059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}